IP Library Granted Patent US 12,582,641
Granted Patent B2
US 12,582,641 · App. 17/433,462 · Granted Mar 24, 2026

Sulfur-containing compound based on glutarimide skeleton and application thereof

Inventors: Xiaobao Yang (Shanghai, CN); Biao Jiang (Shanghai, CN); Xing Qiu (Shanghai, CN); Ning Sun (Shanghai, CN); Renhong Sun (Shanghai, CN); Linyi Liu (Shanghai, CN); Chaowei Ren (Shanghai, CN)
Assignee: SHANGHAITECH UNIVERSITY
A61K31/4545A61K31/454A61K31/4709A61K31/496A61K31/506A61K31/517A61K31/5377A61K31/541A61K31/55A61K31/551A61K45/06A61P35/00C07D401/04C07D401/14C07D405/14C07D409/14C07D413/14C07D471/04C07D471/08C07D491/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,641
App. No.
17/433,462
Granted
Mar 24, 2026
Kind
B2
Abstract

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

Claims (718)

1 . A compound of Formula (Ia)

or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof, wherein

A represents CH 2 or C(O);

Y represents O; and

R, L, and X 1 are as defined in the following (1) or (2);

(1) R represents S, S(O), or S(O) 2 ,

L represents a linear or branched C 1-40 alkylene group optionally substituted one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof, wherein the linear or branched C 1-40 alkylene group is optionally interrupted one or more times by one or more groups selected from:

O, C(O), S, S(O), S(O) 2 , C(O)N(R 1 ), N(R 2 )C(O), N(R 3 ), N(R 4 )C(O)N(R 5 ), wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl,

cycloalkylene optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, and any combination thereof,

arylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

heterocyclylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

heteroarylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

or any combination thereof; and

X 1 represents any one of (a1)-(a8) below:

(a1) NR 6 R 7 , C(O)NR e R f , NHC(O)R 8 , NHC(O)NR 9 R 10 , OR h , or SH, wherein R 6 , R 7 , R e , R f , R h , R 9 , and R 10 each independently represent: (i) H; (ii) linear or branched C 1-10 alkyl optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof; (iii) cycloalkyl optionally substituted with substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, or any combination thereof; (iv) aryl optionally substituted with substituent(s) selected from C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, and hydroxyl; (v) heterocyclyl optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxy; or (vi) heteroaryl optionally substituted with substituent(s) selected from C 1-3 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxy; wherein R 6 and R 7 are not H at the same time; and wherein R 8 represents a linear or branched C 1-8 alkyl, C 5 -C 14 aryl, a 5- to 10-membered heteroaryl, or a 3- to 12-membered heterocyclyl; or

wherein R e and R f together with the nitrogen atom to which they are attached form a 5- to 8-membered heterocyclyl; or

wherein R 6 represents H, and R 7 represents ethyl which is substituted with 2,6-dichloro-3-fluorophenyl; or

wherein R 6 represents H, and R 7 represents thiazolyl which is substituted with C(O)NHR d , wherein R d represents C 1-5 alkyl or 2-chloro-6-methylphenyl; or

wherein R 6 represents H or methyl; and R 7 represents a group of optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, with each group being optionally substituted with substituent(s) selected from: (i) halogen, (ii) C 1-5 alkyl, (iii) di(C 1-6 alkyl)phosphono, (iv) C 1-6 alkylsulfonyl, (v) oxo, (vi) cyano, (vii) 6 -membered aryl optionally substituted with substituent(s) selected from C 1-6 alkyl, halogen and halogenated C 1-3 alkyl, (viii) 5- or 6-membered heterocyclyl optionally substituted with substituent(s) selected from C 1-6 alkyl and halogen, or (ix) 5- or 6-membered heteroaryl optionally substituted with substituent(s) selected from C 1-6 alkyl and halogen;

(a2) quaternary ammonium salt group having the Formula N + R a R b R c X − , wherein R a , R b , and R c each independently represent C 1-20 alkyl group, and X − represents F − , Cl − , Br − , or I − ; or wherein R a and R b together with the nitrogen atom to which they are attached form 5- to 8-membered heterocyclyl, and the ring atoms of the 5- to 8-membered heterocyclyl optionally comprise a heteroatom selected from oxygen, nitrogen, and sulfur, and R c represents C 1-20 alkyl; and X − represents F − , Cl − , Br − , or I − ;

(a3) linear or branched C 1-10 alkyl optionally substituted with one or more fluorine;

(a4) cycloalkyl optionally substituted with substituent(s) selected from halogen, oxo, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, C 1-3 alkoxycarbonyl, or any combination thereof;

(a5) aryl substituted with substituent(s) selected from halogenated C 1-3 alkyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, halogenated C 2-4 alkenyl, or any combination thereof;

(a6) 4-(bromomethyl)-2-fluorophenyl;

(a7) heteroaryl optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, bis(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, and any combination thereof, wherein said optionally substituted phenyl is optionally substituted with substituent(s) selected from the group consisting of C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; or

(a8) a group represented by Formula (G 2 ):

wherein, A 1 represents CH 2 or C(O);

Y 1 represents O; and

Z represents S, S(O), or S(O) 2 ;

or

(2) R represents S,

L represents a linear or branched C 1-40 alkylene group optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof, wherein the linear or branched C 1-40 alkylene group is optionally interrupted one or more times by one or more groups selected from:

O, C(O), S, S(O), S(O) 2 , C(O)N(R 1 ), N(R 2 )C(O), N(R 3 ), N(R 4 )C(O)N(R 5 ), wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl,

cycloalkylene optionally substituted with substituent(s) selected from halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof,

arylene optionally substituted with substituent(s) selected from C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

heterocyclylene optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

heteroarylene optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, or

any combination thereof; and

X 1 represents:

heterocyclyl optionally substituted with substituent(s) selected from halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, C 1-6 alkylsulfonyl, bis(C 1-6 alkyl)phosphono, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, C 1-6 alkyl, or any combination thereof, wherein said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof.

2 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein R, L, and X 1 are as defined in the following (1′) or (2′):

(1′) R represents S, S(O) or S(O) 2 ;

L represents linear or branched C 1-30 alkylene group optionally substituted one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof, wherein the linear or branched C 1-30 alkylene group is optionally interrupted one or more times by one or more groups selected from:

O, C(O), S, S(O), S(O) 2 , C(O)N(R 1 ), N(R 2 )C(O), N(R 3 ), N(R 4 )C(O)N(R 5 ), wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl,

C 3 -C 12 cycloalkylene optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, and any combination thereof,

C 5 -C 14 arylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

3- to 12-membered heterocyclylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

5- to 10-membered heteroarylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

or any combination thereof; and

X 1 represents any one of (b1)-(b7) below:

(b1) NR 6 R 7 , C(O)NR e R f , NHC(O)R 8 , NHC(O)NR 9 R 10 , OR h , or SH, wherein R 6 , R 7 , R e , R f , R h , R 9 , and R 10 each independently represent: H; linear or branched C 1-10 alkyl optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof; C 3 -C 12 cycloalkyl optionally substituted with substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, or any combination thereof; C 5 -C 14 aryl optionally substituted with substituent(s) selected from C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, and hydroxyl; 3- to 12-membered heterocyclyl optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxy; or 5- to 10-membered heteroaryl optionally substituted with substituent(s) selected from C 1-3 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, and hydroxy; wherein R 6 and R 7 are not H at the same time; and wherein R 8 represents a linear or branched C 1-8 alkyl, C 5 -C 14 aryl, a 5- to 10-membered heteroaryl, or a 3- to 12-membered heterocyclyl; or

wherein R e and R f together with the nitrogen atom to which they are attached form a 5- to 8-membered heterocyclyl; or

wherein R 6 represents H, and R 7 represents ethyl which is substituted with 2,6-dichloro-3-fluorophenyl; or

wherein R 6 represents H, and R 7 represents thiazolyl which is substituted with the group of Formula C(O)NHR d , wherein R d represents C 1-5 alkyl or 2-chloro-6-methylphenyl; or

wherein R 6 represents H or methyl; and R 7 represents a group of optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 5 -C 14 aryl, optionally substituted 3- to 12-membered heterocyclyl, or optionally substituted 5- to 10-membered heteroaryl, with each group being optionally substituted with substituent(s) selected from: (i) halogen, (ii) C 1-5 alkyl, (iii) di(C 1-6 alkyl)phosphono, (iv) C 1-6 alkylsulfonyl, (v) oxo, (vi) cyano, (vii) 6-membered aryl optionally substituted with substituent(s) selected from C 1-6 alkyl, halogen and halogenated C 1-3 alkyl, (viii) 5- or 6-membered heterocyclyl optionally substituted with substituent(s) selected from C 1-6 alkyl and halogen, or (ix) 5- or 6-membered heteroaryl optionally substituted with substituent(s) selected from C 1-6 alkyl and halogen;

(b2) quaternary ammonium salt group having the Formula N + R a R b R c X − , wherein R a , R b , and R c each independently represent C 1-10 alkyl group, and X − represents F − , Cl − , Br − , or I − ; or wherein R a and R b together with the nitrogen atom to which they are attached form 5- to 8-membered heterocyclyl, and the ring atoms of the 5- to 8-membered heterocyclyl optionally further comprise a heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and R c represents C 1-20 alkyl; and X − represents F − , Cl − , Br − , or I − ,

(b3) linear or branched C 1-10 alkyl optionally substituted with one or more fluorine,

(b4) C 3 -C 12 cycloalkyl optionally substituted with substituent(s) selected from halogen, oxo, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, C 1-3 alkoxycarbonyl, or any combination thereof,

(b5) C 5 -C 14 aryl substituted with substituent(s) selected from halogenated C 1-3 alkyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, halogenated C 2-4 alkenyl, or any combination thereof,

(b6) 5- to 10-membered heteroaryl optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, bis(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, and any combination thereof, wherein said optionally substituted phenyl is optionally substituted with substituent(s) selected from the group consisting of C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; or

(b7) a group represented by Formula (G 2 ):

wherein, A 1 represents CH 2 or C(O);

Y 1 represents O; and

Z represents S, S(O), or S(O) 2 ;

or

(2′) R represents S,

L represents linear or branched C 1-30 alkylene group optionally substituted with one or more substituent(s) selected from the group consisting of halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, and any combination thereof, wherein the linear or branched C 1-30 alkylene group is optionally interrupted one or more times by one or more groups selected from the group consisting of:

O, C(O), S, S(O), S(O) 2 , C(O)N(R 1 ), N(R 2 )C(O), N(R 3 ), N(R 4 )C(O)N(R 5 ), wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl,

C 3 -C 12 cycloalkylene optionally substituted with substituent(s) selected from halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, and any combination thereof,

C 5 -C 14 arylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

3- to 12-membered heterocyclylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

5- to 10-membered heteroarylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, and

any combination thereof; and

X 1 represents:

3- to 12-membered heterocyclyl optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, C 1-6 alkylsulfonyl, bis(C 1-6 alkyl)phosphono, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, C 1-6 alkyl, and any combination thereof, wherein said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof.

3 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , which is also compound of Formula (Ib):

wherein A, R, L, X 1 , and Y are as defined in claim 1 .

4 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , which is also compound of Formula (Ic):

wherein A, R, L, X 1 , and Y are as defined in claim 1 .

5 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein

L represents the following groups optionally substituted with substituent(s) selected from halogen, C 1-3 alkyl, or any combination thereof:

linear or branched C 1 -C 40 alkylene; *—((CH 2 ) n1 O) m1 —(CH 2 ) n2 —; *—((CH 2 ) n1 O) m1 —(CH 2 ) n2 —O—(CH 2 ) n3 —; *—(CH 2 ) n1 —O—(CH 2 ) n2 —; *—((CR 11 R 12 ) n1 O) m1 —(CR 13 R 14 ) n2 —; *—((CR 15 R 16 ) n1 O) m1 —(CR 17 R 18 ) n2 —O—(CR 19 R 20 ) n3 —; *—(CH 2 ) n1 —S—(CH 2 ) n2 —; *—(CH 2 ) n1 —S(O)—(CH 2 ) n2 —; *—(CH 2 ) n1 —S(O) 2 —(CH 2 ) n2 —; *—(CH 2 ) n1 —N(R 21 )—(CH 2 ) n2 —; *—(CH 2 ) n1 —N(R 22 )C(O)—(CH 2 ) n2 —; *—(CH 2 ) n1 —C(O)N(R 23 )—(CH 2 ) n2 —; *—(CH 2 ) n1 —N(R 24 )C(O)N(R 25 )—(CH 2 ) n2 —; *—(CH 2 ) n1 —(N(R 26 )C(O)—(CH 2 ) n2 ) m1 —; *—(CH 2 ) n1 -piperazinylene-(CH 2 ) n2 —; *—(CH 2 ) n1 -phenylene-(CH 2 ) n2 —; *—(CH 2 ) n1 -phenylene-(CH 2 ) n2 —N(R 21 )—(CH 2 ) n3 —; *—(CH 2 ) n1 -furanylene-(CH 2 ) n2 —; *—(CH 2 ) n1 -furanylene-(CH 2 ) n2 —N(R 21 )—(CH 2 ) n3 —; *—(CH 2 ) n1 -thiazolylene-(CH 2 ) n2 —; *—(CH 2 ) n1 -thiazolylene-C(O)N(R 23 )—(CH 2 ) n2 —; *—(CH 2 ) n1 -thiazolylene-(CH 2 ) n2 —N(R 21 )—(CH 2 ) n3 —; or

linear or branched C 1 -C 40 alkylene group optionally interrupted one or more times by one or more groups selected from: C(O); N(R 21 ); C(O)N(R 23 ); N(R 22 )C(O); C 3 -C 12 cycloalkylene optionally substituted with substituent(s) selected from halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or any combination thereof; C 5 -C 14 arylene optionally substituted with substituent(s) selected from C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy; 3- to 12-membered heterocyclylene optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo; or 5- to 10-membered heteroarylene optionally substituted with substituent(s) selected from C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy; or any combination thereof; or

*—((CH 2 ) n1 O) m1 —(CH 2 ) n2 —, in which the backbone carbon chain is interrupted one or more times by one or more groups selected from: C(O); C 3 -C 12 cycloalkylene optionally substituted with substituent(s) selected from the group consisting of halogen, cyano, C 1-5 alkyl, C 1-3 alkoxy, halogenated C 1-3 alkyl, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, and any combination thereof; C 5 -C 14 arylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, halogenated C 1-3 alkoxy, cyano, C 1-3 alkoxy, halogenated C 1-3 alkyl, halogen, amino, hydroxyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy; 3- to 12-membered heterocyclylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo; 5- to 10-membered heteroarylene optionally substituted with substituent(s) selected from the group consisting of C 1-5 alkyl, C 1-3 alkoxy, cyano, trifluoromethyl, halogen, amino, hydroxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy; or any combination thereof,

wherein * indicates the point of attachment to R;

R 21 , R 22 , R 23 , R 24 , R 25 , and R 26 are each independently selected from H and C 1-3 alkyl;

R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , and R 20 each independently represent H, a linear or branched C 1 -C 10 alkyl, or C 3 -C 10 cycloalkyl group, wherein in the same group L, R 11 , R 12 , R 13 , and R 14 , or R 15 , R 16 , R 17 , R 18 , R 19 , and R 20 are not H at the same time; and

n1, n2, n3, and m1 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

6 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 5 , wherein L represents the following groups optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-3 alkyl, and any combination thereof:

—CH 2 —; —(CH 2 ) 2 —; —(CH 2 ) 3 —; —(CH 2 ) 4 —; —(CH 2 ) 5 —; —(CH 2 ) 6 —; —(CH 2 ) 7 —; —(CH 2 ) 8 —; —(CH 2 ) 9 —; —(CH 2 ) 10 —; —(CH 2 ) 11 —; —(CH 2 ) 12 —; —(CH 2 ) 13 —; —(CH 2 ) 14 —; —(CH 2 ) 15 —; —(CH 2 ) 16 —; —(CH 2 ) 17 —; —(CH 2 ) 18 —; —(CH 2 ) 19 —; or —(CH 2 ) 20 —.

7 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 5 , wherein L represents the following groups optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-3 alkyl, and any combination thereof:

*—CH 2 CH 2 O(CH 2 ) 2 —; *—(CH 2 CH 2 O) 2 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 3 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 4 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 5 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 6 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 7 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 8 —(CH 2 ) 2 —; *—(CH 2 CH 2 O) 9 (CH 2 ) 2 —; *—(CH 2 CH 2 O) 10 (CH 2 ) 2 —; *—CH 2 CH 2 OCH 2 —; *—(CH 2 CH 2 O) 2 —CH 2 —; *—(CH 2 CH 2 O) 3 —CH 2 —; *—(CH 2 CH 2 O) 4 —CH 2 —; *—(CH 2 CH 2 O) 5 —CH 2 —; *—(CH 2 CH 2 O) 6 —CH 2 —; *—(CH 2 CH 2 O) 7 —CH 2 —; *—(CH 2 CH 2 O) 8 —CH 2 —; *—(CH 2 CH 2 O) 9 —CH 2 —; *—(CH 2 CH 2 O) 10 —CH 2 —; *—CH 2 CH 2 O(CH 2 ) 3 —; *—(CH 2 CH 2 O) 2 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 3 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 4 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 5 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 6 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 7 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 8 —(CH 2 ) 3 —; *—(CH 2 CH 2 O) 9 (CH 2 ) 3 —; *—(CH 2 CH 2 O) 10 (CH 2 ) 3 —; *—CH 2 CH 2 OCH 2 CH 2 CH 2 OCH 2 —; *—CH 2 CH 2 OCH 2 CH 2 CH 2 O—(CH 2 ) 2 —; *—CH 2 CH 2 OCH 2 CH 2 CH 2 O—(CH 2 ) 3 —; *—(CH 2 CH 2 O) 2 (CH 2 CH 2 CH 2 O)(CH 2 ) 3 —; *—(CH 2 CH 2 O) 2 (CH 2 CH 2 CH 2 O) 2 (CH 2 ) 3 —; *—(CH 2 ) 1 O(CH 2 ) 1 —; *—(CH 2 ) 1 O(CH 2 ) 2 —; *—(CH 2 ) 2 O(CH 2 ) 4 —; *—(CH 2 ) 2 O(CH 2 ) 5 —; *—(CH 2 ) 2 O(CH 2 ) 6 —; *—(CH 2 ) 3 O(CH 2 ) 1 —; *—(CH 2 ) 3 O(CH 2 ) 2 —; *—(CH 2 ) 3 O(CH 2 ) 3 —; *—(CH 2 ) 4 O(CH 2 ) 1 —; *—(CH 2 ) 4 O(CH 2 ) 2 —; *—(CH 2 ) 4 O(CH 2 ) 3 —; *—(CH 2 ) 5 O(CH 2 ) 1 —; *—(CH 2 ) 5 O(CH 2 ) 2 —; *—(CH 2 ) 5 O(CH 2 ) 3 —; *—(CH 2 ) 5 O(CH 2 ) 4 —; or *—(CH 2 ) 5 O(CH 2 ) 5 —;

wherein * indicates the point of attachment to R.

8 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 5 , wherein L represents the following groups optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-3 alkyl, and any combination thereof:

*—(CH 2 ) 1 —NH—(CH 2 ) 1 —; *—(CH 2 ) 2 —NH—(CH 2 ) 1 —; *—(CH 2 ) 2 —NH—(CH 2 ) 2 —; *—(CH 2 ) 2 —NH—(CH 2 ) 3 —; *—(CH 2 ) 2 —NH—(CH 2 ) 4 —; *—(CH 2 ) 2 —NH—(CH 2 ) 5 —; *—(CH 2 ) 2 —NH—(CH 2 ) 6 —; *—(CH 2 ) 2 —NH—(CH 2 ) 7 —; *—(CH 2 ) 2 —NH—(CH 2 ) 8 —; *—(CH 2 ) 2 —NH—(CH 2 ) 9 —; *—(CH 2 ) 2 —NH—(CH 2 ) 10 —; *—(CH 2 ) 2 —NH—(CH 2 ) 11 —; *—(CH 2 ) 2 —NH—(CH 2 ) 12 —; *—(CH 2 ) 3 —NH—(CH 2 ) 1 —; *—(CH 2 ) 3 —NH—(CH 2 ) 2 —; *—(CH 2 ) 3 —NH—(CH 2 ) 3 —; *—(CH 2 ) 4 —NH—(CH 2 ) 1 —; *—(CH 2 ) 4 —NH—(CH 2 ) 2 —; *—(CH 2 ) 5 —NH—(CH 2 ) 3 —; *—(CH 2 ) 5 —NH—(CH 2 ) 1 —; *—(CH 2 ) 5 —NH—(CH 2 ) 2 —; *—(CH 2 ) 8 —NH—(CH 2 ) 2 —; *—(CH 2 ) 5 —NH—(CH 2 ) 3 —; *—(CH 2 ) 5 —NH—(CH 2 ) 4 —; *—(CH 2 ) 5 —NH—(CH 2 ) 5 —; *—(CH 2 ) 1 —N(CH 3 )—(CH 2 ) 8 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 1 —; *—(CH 2 ) 3 —N(CH 3 )—(CH 2 ) 1 —; *—(CH 2 ) 4 —N(CH 3 )—(CH 2 ) 1 —; *—(CH 2 ) 5 —N(CH 3 )—(CH 2 ) 1 —; *—(CH 2 ) 6 —N(CH 3 )—(CH 2 ) 1 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 2 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 3 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 4 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 5 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 6 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 7 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 8 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 9 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 10 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 11 —; *—(CH 2 ) 2 —N(CH 3 )—(CH 2 ) 12 —; *—(CH 2 ) 2 —NHC(O)—CH 2 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 2 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 3 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 4 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 5 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 6 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 7 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 8 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 9 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 10 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 11 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 12 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 13 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 14 —; *—(CH 2 ) 2 —NHC(O)—(CH 2 ) 15 —; *—(CH 2 ) 3 —NHC(O)—CH 2 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 2 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 3 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 4 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 5 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 6 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 7 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 8 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 9 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 10 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 11 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 12 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 13 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 14 —; *—(CH 2 ) 3 —NHC(O)—(CH 2 ) 15 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 1 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 2 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 3 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 4 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 5 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 6 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 7 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 8 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 9 —; *—(CH 2 ) 4 NHC(O)(CH 2 ) 10 —; *—(CH 2 ) 5 NHC(O)(CH 2 ) 1 —; *—(CH 2 ) 8 NHC(O)(CH 2 ) 2 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—CH 2 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 2 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 3 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 4 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 5 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 6 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 7 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ); —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 9 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 10 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 11 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 12 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 13 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 14 —; *—(CH 2 ) 2 —N(CH 3 )C(O)—(CH 2 ) 15 —; *—(CH 2 ) 2 —C(O)NH—CH 2 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 2 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 3 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 4 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 5 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 6 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 7 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 8 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 9 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 10 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 11 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 12 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 13 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 14 —; *—(CH 2 ) 2 —C(O)NH—(CH 2 ) 15 —; *—(CH 2 ) 3 —C(O)NH—CH 2 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 2 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 3 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 4 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 5 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 6 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 7 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 8 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 9 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 10 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 11 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 12 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 13 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 14 —; *—(CH 2 ) 3 —C(O)NH—(CH 2 ) 15 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 1 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 2 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 3 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 4 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 5 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 6 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 7 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 8 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 9 —; *—(CH 2 ) 4 C(O)NH(CH 2 ) 10 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—CH 2 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 2 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 3 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 4 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 5 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 6 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 7 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 8 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 9 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 10 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 11 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 12 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 13 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 14 —; *—(CH 2 ) 2 —C(O)N(CH 3 )—(CH 2 ) 15 —; *—(CH 2 ) 2 —NHC(O)NH—(CH 2 ) 4 —; *—(CH 2 ) 4 —NHC(O)NH—(CH 2 ) 2 —; *—CH 2 —NHC(O)NH—(CH 2 ) 2 —; *—(CH 2 ) 2 —NHC(O)NH—CH 2 —; *—(CH 2 ) 2 —NHC(O)NH—(CH 2 ) 2 —; *—(CH 2 ) 2 —NHC(O)NH—(CH 2 ) 3 —; *—(CH 2 ) 3 —NHC(O)NH—(CH 2 ) 2 —; *—CH 2 -piperazinylene-CH 2 —; *—(CH 2 ) 2 -piperazinylene-(CH 2 ) 2 —; *—(CH 2 ) 2 -piperazinylene-(CH 2 ) 3 —; *—(CH 2 ) 2 -piperazinylene-(CH 2 ) 4 —; *—(CH 2 ) 2 -piperazinylene-(CH 2 ) 5 —; *—(CH 2 ) 3 -piperazinylene-CH 2 —; *—(CH 2 ) 3 -piperazinylene-(CH 2 ) 2 —; *—(CH 2 ) 3 -piperazinylene-(CH 2 ) 3 —; *—(CH 2 ) 4 -piperazinylene-CH 2 —; *—(CH 2 ) 4 -piperazinylene-(CH 2 ) 2 —; *—(CH 2 ) 4 -piperazinylene-(CH 2 ) 3 —; *—(CH 2 ) 8 -piperazinylene-CH 2 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 2 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 3 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 4 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 5 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 6 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 7 —; *—(CH 2 ) 8 -piperazinylene-(CH 2 ) 8 —; *—CH 2 -piperazinylene-(CH 2 ) 8 —; *—(CH 2 ) 2 -piperazinylene-(CH 2 ) 8 —; *—(CH 2 ) 3 -piperazinylene-(CH 2 ) 8 —; *—(CH 2 ) 4 -piperazinylene-*—(CH 2 ) 5 -piperazinylene-(CH 2 ) 8 —; *—(CH 2 ) 6 -piperazinylene-(CH 2 ) 8 —; *—(CH 2 ) 7 —(CH 2 ) 8 —; piperazinylene-(CH 2 ) 8 —; *—CH 2 -phenylene-CH 2 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 5 —; *—(CH 2 ) 3 -phenylene-CH 2 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 4 -phenylene-CH 2 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 5 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 6 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 7 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 8 -phenylene-CH 2 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 5 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 6 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 5 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 6 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 7 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 8 —; *—CH 2 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 5 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 6 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 7 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 1 S(CH 2 ) 1 —; *—(CH 2 ) 2 S(CH 2 ) 2 —; *—(CH 2 ) 2 S(CH 2 ) 1 —; *—(CH 2 ) 1 S(CH 2 ) 2 —; *—(CH 2 ) 1 S(CH 2 ) 3 —; *—(CH 2 ) 1 S(CH 2 ) 4 —; *—(CH 2 ) 2 S(CH 2 ) 3 —; *—(CH 2 ) 2 S(CH 2 ) 4 —; *—(CH 2 ) 2 S(CH 2 ) 5 —; *—(CH 2 ) 3 S(CH 2 ) 1 —; *—(CH 2 ) 3 S(CH 2 ) 2 —; *—(CH 2 ) 3 S(CH 2 ) 3 —; *—(CH 2 ) 4 S(CH 2 ) 1 —; *—(CH 2 ) 4 S(CH 2 ) 2 —; *—(CH 2 ) 4 S(CH 2 ) 3 —; *—(CH 2 ) 5 S(CH 2 ) 1 —; *—(CH 2 ) 5 S(CH 2 ) 2 —; *—(CH 2 ) 5 S(CH 2 ) 3 —; *—(CH 2 ) 6 S(CH 2 ) 1 —; *—(CH 2 ) 6 S(CH 2 ) 2 —; *—(CH 2 ) 6 S(CH 2 ) 3 —; *—(CH 2 ) 7 S(CH 2 ) 1 —; *—(CH 2 ) 7 S(CH 2 ) 2 —; *—(CH 2 ) 7 S(CH 2 ) 3 —; *—(CH 2 ) 8 S(CH 2 ) 1 —; *—(CH 2 ) 8 S(CH 2 ) 2 —; *—(CH 2 ) 8 S(CH 2 ) 3 —; *—(CH 2 ) 9 S(CH 2 ) 1 —; *—(CH 2 ) 9 S(CH 2 ) 2 —; *—(CH 2 ) 9 S(CH 2 ) 3 —; *—(CH 2 ) 1 S(O)(CH 2 ) 1 —; *—(CH 2 ) 2 S(O)(CH 2 ) 2 —; *—(CH 2 ) 2 S(O)(CH 2 ) 1 —; *—(CH 2 ) 1 S(O)(CH 2 ) 2 —; *—(CH 2 ) 1 S(O)(CH 2 ) 3 —; *—(CH 2 ) 1 S(O)(CH 2 ) 4 —; *—(CH 2 ) 2 S(O)(CH 2 ) 3 —; *—(CH 2 ) 2 S(O)(CH 2 ) 4 —; *—(CH 2 ) 2 S(O)(CH 2 ) 5 —; *—(CH 2 ) 3 S(O)(CH 2 ) 1 —; *—(CH 2 ) 3 S(O)(CH 2 ) 2 —; *—(CH 2 ) 3 S(O)(CH 2 ) 3 —; *—(CH 2 ) 4 S(O)(CH 2 ) 1 —; *—(CH 2 ) 4 S(O)(CH 2 ) 2 —; *—(CH 2 ) 4 S(O)(CH 2 ) 3 —; *—(CH 2 ) 5 S(O)(CH 2 ) 1 —; *—(CH 2 ) 5 S(O)(CH 2 ) 2 —; *—(CH 2 ) 5 S(O)(CH 2 ) 3 —; *—(CH 2 ) 6 S(O)(CH 2 ) 1 —; *—(CH 2 ) 6 S(O)(CH 2 ) 2 —; *—(CH 2 ) 6 S(O)(CH 2 ) 3 —; *—(CH 2 ) 7 S(O)(CH 2 ) 1 —; *—(CH 2 ) 7 S(O)(CH 2 ) 2 —; *—(CH 2 ) 7 S(O)(CH 2 ) 3 —; *—(CH 2 ) 8 S(O)(CH 2 ) 1 —; *—(CH 2 ) 8 S(O)(CH 2 ) 2 —; *—(CH 2 ) 8 S(O)(CH 2 ) 3 —; *—(CH 2 ) 9 S(O)(CH 2 ) 1 —; *—(CH 2 ) 9 S(O)(CH 2 ) 2 —; *—(CH 2 ) 9 S(O)(CH 2 ) 3 —; *—(CH 2 ) 1 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 2 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 2 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 1 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 1 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 1 S(O) 2 (CH 2 ) 4 —; *—(CH 2 ) 2 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 2 S(O) 2 (CH 2 ) 4 —; *—(CH 2 ) 2 S(O) 2 (CH 2 ) 5 —; *—(CH 2 ) 3 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 3 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 3 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 4 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 4 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 4 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 5 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 5 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 5 S(O)(CH 2 ) 3 —; *—(CH 2 ) 6 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 6 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 6 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 7 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 7 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 7 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 8 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 8 S(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 8 S(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 9 S(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 9 S(O) 2 (CH 2 ) 2 —; or *—(CH 2 ) 9 S(O) 2 (CH 2 ) 3 —;

wherein * indicates the point of attachment to R.

9 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 5 , wherein L represents the following groups optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-3 alkyl, and any combination thereof:

*—(CH 2 ) 6 —NH—(CH 2 ) 1 —; *—(CH 2 ) 6 —NH—(CH 2 ) 3 —; *—(CH 2 ) 6 —NH—(CH 2 ) 4 —; *—(CH 2 ) 6 —NH—(CH 2 ) 5 —; *—(CH 2 ) 7 —NH—(CH 2 ) 1 —; *—(CH 2 ) 7 —NH—(CH 2 ) 2 —; *—(CH 2 ) 7 —NH—(CH 2 ) 3 —; *—(CH 2 ) 7 —NH—(CH 2 ) 4 —; *—(CH 2 ) 6 —NH—CH(CH 3 )—; *—(CH 2 ) 5 —NH—CH(CH 3 )—; *—(CH 2 ) 4 —NH—CH(CH 3 )—; *—(CH 2 ) 3 —NH—CH(CH 3 )—; *—(CH 2 ) 2 —NH—CH(CH 3 )—; *—(CH 2 ) 7 —NH—CH(CH 3 )—; *—(CH 2 ) 8 —NH—CH(CH 3 )—; *—(CH 2 ) 7 —NH—CH(CF 3 )—; *—(CH 2 ) 6 —NH—CH(CF 3 )—; *—(CH 2 ) 5 —NH—CH(CF 3 )—; *—(CH 2 ) 4 —NH—CH(CF 3 )—; *—(CH 2 ) 3 —NH—CH(CF 3 )—; *—(CH 2 ) 2 —NH—CH(CF 3 )—; *—(CH 2 ) 8 —NH—CH(CF 3 )—; *—CH 2 —C(O)NH—(CH 2 ) 4 —; *—CH 2 —C(O)NH—(CH 2 ) 2 —; *—CH 2 —C(O)NH—(CH 2 ) 3 —; *—CH 2 —C(O)NH—(CH 2 ) 5 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 2 —; *—CH 2 -phenylene-CH 2 —NH—CH(CH 3 )—; *—CH 2 -phenylene-(CH 2 ) 2 —NH—CH(CH 3 )—; *—CH 2 -phenylene-CH 2 —NH—CH 2 —; *—CH 2 -phenylene-(CH 2 ) 2 —NH—CH 2 —; *—(CH 2 ) 1 —C(O)NH—(CH 2 ) 4 —; *—(CH 2 ) 1 -furanylene-(CH 2 ) 1 —; *—(CH 2 ) 1 -furanylene-(CH 2 ) 2 —; *—(CH 2 ) 1 -furanylene-(CH 2 ) 3 —; *—(CH 2 ) 2 -furanylene-(CH 2 ) 1 —; *—(CH 2 ) 2 -furanylene-(CH 2 ) 2 —; *—(CH 2 ) 3 -furanylene-(CH 2 ) 1 —; *—(CH 2 ) 3 -furanylene-(CH 2 ) 2 —; *—(CH 2 ) 1 -thiazolylene-(CH 2 ) 1 —; *—(CH 2 ) 1 -thiazolylene-(CH 2 ) 2 —; *—(CH 2 ) 1 -thiazolylene-(CH 2 ) 3 —; *—(CH 2 ) 2 -thiazolylene-(CH 2 ) 1 —; *—(CH 2 ) 2 -thiazolylene-(CH 2 ) 2 —; *—(CH 2 ) 3 -thiazolylene-(CH 2 ) 1 —; *—(CH 2 ) 3 -thiazolylene-(CH 2 ) 2 —; or *—CH 2 -thiazolylene-CH 2 —NH—CH 2 —;

wherein * indicates the point of attachment to R.

10 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 5 , wherein L represents the following groups optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-3 alkyl, and any combination thereof:

wherein * indicates the point of attachment to R.

11 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

C(O)NH 2 , piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(O)CH 3 , OH, adamantanyl-O—, norcamphanyl-O—, 1,7,7-trimethyl-bicyclo[2.2.1]heptanyl-O—, or SH.

12 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

2-isopropyl-5-methylcyclohexyl-O—, adamantan-1-yl-O—, adamantan-2-yl-O—, adamantanyl-NHC(O)—, 3,5-dimethyladamantan-1-yl-NHC(O)—, adamantan-2-yl-NHC(O)—, or NHC(O)CH 3 .

13 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents a linear or branched C 1-10 alkyl group optionally substituted with one or more fluorine.

14 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 13 , wherein X 1 represents CF 2 CF 3 , or CF 3 .

15 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents C 3 -C 12 cycloalkyl group optionally substituted with substituent(s) selected from halogen, oxo, cyano, C 1-3 alkoxy, trifluoromethyl, amino, hydroxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-5 alkyl, or any combination thereof.

16 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 15 , wherein X 1 represents cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, or adamantanyl.

17 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 15 , wherein X 1 represents cyclopropyl, 2,3-dihydro-1H-indenyl, or 4-cyano-2,3-dihydro-1H-indenyl.

18 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 15 , wherein X 1 represents adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, or (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl.

19 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein R a , R b , and R c each independently represent a C 1-10 alkyl group.

20 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein R a and R b each independently represent methyl, ethyl, propyl, isopropyl or butyl; R c represents ethyl; and X − represents Cl − .

21 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein R a , R b , and R c all represent ethyl, and X − represents Cl − ; or wherein R a , R b and R c all represent methyl, and X − represents Cl − .

22 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

23 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents C 5 -C 14 aryl group substituted with substituent(s) selected from halogenated C 1-3 alkyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-5 alkyl, halogenated C 2-4 alkenyl, or any combination thereof.

24 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 23 , wherein X 1 represents phenyl or naphthyl which are each independently substituted with substituent(s) selected from halogenated C 1-3 alkyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-5 alkyl, halogenated C 2-4 alkenyl, or any combination thereof.

25 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein under (2), X 1 represents optionally substituted 3- to 12-membered heterocyclyl, or under (1), X 1 represents optionally substituted 5- to 10-membered heteroaryl,

wherein said optionally substituted 3- to 12-membered heterocyclyl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogen, oxo, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, bis(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl group, or any combination thereof, wherein said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and

said optionally substituted 5- to 10-membered heteroaryl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, bis(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, optionally substituted phenyl, optionally substituted 5- or 6-membered heterocyclyl, or optionally substituted 5- or 6-membered heteroaryl group, or any combination thereof, wherein said optionally substituted phenyl is optionally substituted with substituent(s) selected from C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof; and said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof.

26 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 25 , wherein the optionally substituted 3- to 12-membered heterocyclyl is

optionally substituted morpholinyl; optionally substituted piperidinyl; optionally substituted piperazinyl; optionally substituted 1,4-diazepan-1-yl; optionally substituted 3,8-diazabicyclo[3.2.1]octan-3-yl; optionally substituted 2-azabicyclo[3.2.1]octanyl; optionally substituted 1,4-diazabicyclo[3.2.1]octanyl; optionally substituted 2,5-diazabicyclo[2.2.2]octan-2-yl; optionally substituted pyrrolidinyl; optionally substituted tetrahydro-2H-pyranyl; optionally substituted azacycloheptyl; optionally substituted azacyclooctyl; optionally substituted substituted 5-azaspiro[2.4]heptyl; optionally substituted 6-thiomorpholino; optionally azaspiro[2.5]octyl; optionally substituted 2-oxa-7-azaspiro[3.5]nonyl; optionally substituted 3-azabicyclo[3.1.0]hexyl; optionally substituted 3-azabicyclo[4.1.0]heptyl; optionally substituted 3-azaspiro[5.5]undecan-3-yl; optionally substituted hexahydro-1H-isoindol-2 (3H)-yl; optionally substituted (3aR,7aS)-hexahydro-1H-isoindol-2 (3H)-yl; optionally substituted (3aR,7aS)-octahydro-2H-isoindol-2-yl; optionally substituted azetidinyl; or [1,4′-dipiperidin]-1′-yl;

wherein the optionally substituted groups are each independently optionally substituted with substituent(s) selected from the group consisting of C 1-6 alkyl, halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, di(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, oxo, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl group, and any combination thereof, wherein said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from the group consisting of: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, and any combination thereof; and

wherein the optionally substituted 5- to 10-membered heteroaryl is an optionally substituted quinazolinyl; optionally substituted pyridyl; optionally substituted pyrimidinyl; optionally substituted thiazolyl; optionally substituted quinolyl; optionally substituted indolyl; optionally substituted benzothienyl; optionally substituted isoindolyl; optionally substituted 5,7-dihydro-6H-pyrrolo[3,4-b]pyridyl; or optionally substituted benzofuranyl;

wherein the optionally substituted groups are each independently optionally substituted with substituent(s) selected from C 1-6 alkyl, halogen, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, di(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl group, or any combination thereof, wherein said optionally substituted phenyl is optionally substituted with substituent(s) selected from C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof; and said optionally substituted 5- or 6-membered heterocyclyl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, cyano, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof; and said optionally substituted 5- or 6-membered heteroaryl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogenated C 1-3 alkyl, amino, hydroxyl, halogen, or any combination thereof.

27 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 26 , wherein the optionally substituted 3- to 12-membered heterocyclyl or optionally substituted 5- to 10-membered heteroaryl is:

morpholinyl; piperidinyl; 2-oxopiperidin-1-yl; piperazinyl; N-methylpiperazinyl; 4-(methylsulfonyl)piperazin-1-yl; 4-(ethylsulfonyl)piperazin-1-yl; (N-methylpiperazinyl) piperidinyl; 3,5-dimethylpiperazinyl; 1,4-diazepan-1-yl; 4-methyl-1,4-diazepan-1-yl; 1-methyl-1,4-diazepan-1-yl; 8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl; 1,4-diazabicyclo[3.2.1]octan-4-yl; 5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl; 8,8-difluoro-2-azabicyclo[3.2.1]octan-2-yl; 2-oxopyrrolidin-1-yl; 3-fluoro-4-hydroxypyrrolidin-1-yl; 3-methyl-4-(trifluoromethyl) pyrrolidin-1-yl; 2,6-dioxopiperidin-3-yl; 4,4-dimethylpiperidin-1-yl; 3,5-dimethylpiperidin-1-yl; 4,4-difluoropiperidin-1-yl; 4-methylpiperazin-1-yl; tetrahydro-2H-pyran-2-yl; pyridyl; pyrimidinyl; thiazolyl; quinolyl; 6,7-difluoroquinazolin-4-yl; 3-cyano-quinolyl; indolyl; 1-methyl-1H-indol-7-yl; benzothienyl; benzofuranyl; quinazolinyl; 6,7-difluoroquinazolin-4-yl; pyrrolidinyl; pyrrolidin-1-yl; 4-(pyridin-3-yl)pyrimidin-2-yl; 3-cyanoazetidinyl; 3-hydroxyazetidinyl; 3-hydroxy-3-methylazetidinyl; 3-hydroxy-2-methylazetidin-1-yl; 3-(trifluoromethoxy) azetidin-1-yl; azepan-1-yl; azacyclooctan-1-yl; 7-fluoro-5-azaspiro[2.4]heptan-5-yl; 1,1-difluoro-5-azaspiro[2.4]heptan-5-yl; 1,1-difluoro-6-azaspiro[2.5]octan-6-yl; 6-azaspiro[2.5]octan-6-yl; 2-oxa-7-azaspiro[3.5]nonan-7-yl; 3-azabicyclo[3.1.0]hexan-3-yl; 6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl; 3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl; 3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl; isoindol-2-yl; thiomorpholino; [1,4′-dipiperidin]-1′-yl; 4,4-difluoropiperidinyl; or

28 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents an optionally substituted C 3 -C 12 cycloalkyl or substituted C 5 -C 14 aryl,

wherein said optionally substituted C 3 -C 12 cycloalkyl is optionally substituted with substituent(s) selected from: C 1-6 alkyl, halogen, C 1-3 alkoxycarbonyl, or any combination thereof; and

wherein said substituted C 5 -C 14 aryl is substituted with substituent(s) selected from: halogenated C 2-4 alkenyl.

29 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 28 , wherein X 1 represents:

(2-bromovinyl)phenyl, or

30 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

NR 6 R 7 ,

wherein R 6 and R 7 each independently represent H or a linear or branched C 1-10 alkyl group optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof, provided that R 6 and R 7 are not H at the same time.

31 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 30 , wherein X 1 represents NHCH 3 , N(CH 3 ) 2 , N(CH 2 CH 3 ) 2 , or N(CH(CH 3 ) 2 ) 2 .

32 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

NR 6 R 7 ,

wherein R 6 represents H or methyl; and

R 7 represents pyrimidinyl, pyridyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-(dimethylphosphono)phenyl, 2-(isopropylsulfonyl)phenyl, 4-(pyridin-3-yl)pyrimidin-2-yl, indolyl, 1-methyl-1H-indol-7-yl, benzothienyl, benzo[b]thien-7-yl, benzofuran-7-yl, benzofuranyl, 3-cyano-quinol-4-yl, quinolyl, thiazolyl, adamantanyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 4-(4-methylpiperazin-1-yl) piperidin-1-yl, cyclohexyl, dimethylcyclohexyl, 4,4-dimethylcyclohexyl, spiro-cycloalkyl, spiro[5.5]undec-3-yl, spiro[3.3]heptyl, spiro[3.3]hept-2-yl, pyrrolidinyl, azepanyl, azacyclooctanyl, piperidinyl, dimethylpiperidinyl, or azaspirocycloalkyl.

33 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents:

NR 6 R 7 ,

wherein R 6 represents H, methyl, ethyl, isopropyl, or cyclohexyl; and

R 7 represents the following groups:

adamantanyl, noradamantanyl, norcamphanyl, cyclohexyl, cyclopentyl, cyclopropyl, cyclobutyl, ethyl, isopropyl, tert-butyl, methyl, 2,4-dimethylpent-3-yl, dicyclopropylmethyl, spiro[3.3]heptyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.2]octyl, 4,4-dimethylcyclohexyl, oxetanyl, oxazolyl, 2,3-dihydro-1H-indenyl, quinuclidinyl, 1,7,7-trimethylbicyclo[2.2.1]heptyl, 7,7-dimethylbicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptyl, or 1-cyclopropylethyl.

34 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 33 , wherein R 7 represents:

bicyclo[1.1.1]pent-1-yl, 4,4-dimethylcyclohexyl, 2-methoxycyclopropyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3,3-difluoro-1-(2-(trifluoromethyl)phenyl)cyclobutyl, 3-(2-(trifluoromethyl)phenyl) oxetan-3-yl, 3,3-difluorocyclopentyl, 3-hydroxycyclohexyl, 3-hydroxycyclohexyl, 3-cyano-bicyclo[1.1.1]pent-1-yl, bicyclo[2.2.2]octan-1-yl, 4-hydroxybicyclo[2.2.2]octan-1-yl, 2-isopropyl-5-methylcyclohexyl, 5-methyloxazol-2-yl, 4-cyano-2,3-dihydro-1H-inden-1-yl, 2,4-dimethylpentan-3-yl, dicyclopropylmethyl, quinuclidin-3-yl, (S)-quinuclidin-3-yl, (R)-quinuclidin-3-yl, adamantan-1-yl, 3-hydroxyadamantanyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl, 3,5-dimethyladamantanyl, 3,5-dimethyladamantan-1-yl, hexahydro-2,5-methanopentalen-3a (1H)-yl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptan-2-yl, 1-cyclopropylethyl, or

35 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 ,

wherein X 1 represents NR 6 R 7 , wherein R 6 represents H, and R 7 represents pyrimidin-4-yl, pyridin-4-yl, or quinazolin-4-yl; or

wherein X 1 represents NR 6 R 7 , wherein R 6 and R 7 represent phenyl.

36 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein X 1 represents NHC(O)NR 9 R 10 , wherein R 9 represents H, and R 10 represents adamantanyl, adamantan-1-yl, adamantan-2-yl, 3,5-dimethyladamantan-1-yl, phenyl, or 3-chloro-4-methylphenyl.

37 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein the compound is selected from:

4-((6-(diethylamino)hexyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((6-(dimethylamino)hexyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((6-(methylamino)hexyl)thio)isoindoline-1,3-dione;

3-(4-((3-hydroxypropyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-hydroxypentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-hydroxyoctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)acetamide;

3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)thio)nonyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((9-((4,4,5,5,5-pentafluoropentyl) sulfonyl)nonyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((9,9,10,10,10-pentafluorodecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-morpholinoethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(piperazin-1-yl)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(piperidin-1-yl)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(diethylamino)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(diisopropylamino)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-morpholinopropyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-(piperazin-1-yl)propyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-(piperidin-1-yl)propyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(diethylamino)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(diisopropylamino)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-morpholinobutyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(piperazin-1-yl)butyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(piperidin-1-yl)butyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(diethylamino)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(diisopropylamino)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-morpholinopentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((5-(piperazin-1-yl)pentyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((5-(piperidin-1-yl)pentyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-(diethylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-(diisopropylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-(dimethylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-(methylamino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)pentyl)acetamide;

3-(4-((6-morpholinohexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((6-(piperazin-1-yl)hexyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((6-(piperidin-1-yl)hexyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(diethylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(diisopropylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(dimethylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(methylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-morpholinoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(piperazin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(piperidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(diethylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(diisopropylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-morpholinooctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(piperazin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(4-methylpiperazin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(3,5-dimethylpiperazin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(piperidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(4,4-difluoropiperidin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(1,4-diazepan-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(4-methyl-1,4-diazepan-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(4-(piperazin-1-yl) piperidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(4-(4-methylpiperazin-1-yl) piperidin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(diisopropylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-((2-(diethylamino)ethyl)amino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N-(2-morpholinoethyl) pentanamide;

N-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)butyl)-3-morpholinopropanamide;

3-(4-((8-(diethylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(dimethylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(methylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((9-morpholinononyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((9-(piperazin-1-yl)nonyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((9-(piperidin-1-yl)nonyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((9-(diethylamino)nonyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((9-(diisopropylamino)nonyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((10-morpholinodecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((10-(piperazin-1-yl)decyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((10-(piperidin-1-yl)decyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((10-(diethylamino)decyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((10-(diisopropylamino)decyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((11-morpholinoundecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((11-(piperazin-1-yl)undecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((11-(piperidin-1-yl)undecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((11-(diethylamino)undecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((11-(diisopropylamino)undecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((2-(diethylamino)ethyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((12-morpholinododecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((12-(piperazin-1-yl) dodecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((12-(piperidin-1-yl) dodecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((12-(diethylamino) dodecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((12-(diisopropylamino) dodecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)-3-morpholinopropanamide;

3-(4-((15-morpholinopentadecyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((15-(piperidin-1-yl)pentadecyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(4-(2-morpholinoethyl)phenyl)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(4-((3,3-difluorocyclobutyl)methyl)piperazin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-((2-hydroxyethyl)amino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(2-oxopiperidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(2-oxopyrrolidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

1-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(pyrimidin-4-ylamino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(pyridin-4-ylamino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-(quinazolin-4-ylamino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((6,7-difluoroquinazolin-4-yl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((4-fluorophenyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((3,5-difluorophenyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-((3,4,5-trifluorophenyl)amino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((2-(dimethylphosphoryl)phenyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((2-(isopropylsulfonyl)phenyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((8-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

N-(2-chloro-6-methylphenyl)-2-((8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)amino)thiazole-5-carboxamide;

3-(4-((8-((1-(2,6-dichloro-3-fluorophenyl)ethyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((1-methyl-1H-indol-7-yl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(benzo[b]thiophen-7-ylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-(benzofuran-7-ylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

4-((8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)amino) quinoline-3-carbonitrile;

8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N-ethyl-N,N-diisopropyloctan-1-aminium chloride;

8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N,N,N-triethyloctan-1-aminium chloride;

8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N,N,N-trimethyloctan-1-aminium chloride;

4-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)-4-methylmorpholin-4-ium chloride;

1-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)-1-methylpiperidin-1-ium chloride;

3-(4-((4-((adamantan-1-yl)amino)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-((adamantan-1-yl)amino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((adamantan-1-yl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((adamantan-1-yl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((adamantan-2-yl)amino)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-((adamantan-2-yl)amino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((adamantan-2-yl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((adamantan-2-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((adamantan-2-yl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-((adamantan-2-yl)amino)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(2-((adamantan-2-yl)amino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-(adamantan-1-yl)-3-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)hexyl)urea;

1-(4-(adamantan-1-yl)butyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)ethyl)urea;

3-(4-((8-((adamantan-1-yl)(methyl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((8-((3,5-dimethyladamantan-1-yl)amino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((9-(adamantan-1-yl)nonyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

2-((adamantan-1-yl)amino)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)pentyl)acetamide;

3-(1-oxo-4-((8-(((1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-morpholinoethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(2-(piperazin-1-yl)ethoxy)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(diethylamino)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(dimethylamino)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(methylamino)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(3-morpholinopropoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(3-(piperazin-1-yl)propoxy)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(2-morpholinoethoxy)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(2-(2-(piperazin-1-yl)ethoxy)ethoxy)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(2-(diethylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(2-(dimethylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(3-(3-morpholinopropoxy)propoxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2-(3-(3-(piperazin-1-yl)propoxy)propoxy)ethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-(2-morpholinoethoxy)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-((5-morpholinopentyl)oxy)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)ethyl)urea;

1-(3-chloro-4-methylphenyl)-3-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)propyl)urea;

1-(3-chloro-4-methylphenyl)-3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)butyl)urea;

1-(3-chloro-4-methylphenyl)-3-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)pentyl)urea;

1-(3-chloro-4-methylphenyl)-3-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)hexyl)urea;

1-(3-chloro-4-methylphenyl)-3-(7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl)urea;

1-(3-chloro-4-methylphenyl)-3-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)octyl)urea;

1-(3-chloro-4-methylphenyl)-3-(9-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)nonyl)urea;

1-(3-chloro-4-methylphenyl)-3-(10-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)decyl)urea;

1-(3-chloro-4-methylphenyl)-3-(11-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)undecyl)urea;

3,3′-((octane-1,8-diylbis(sulfanediyl))bis(1-oxoisoindoline-4,2-diyl))bis(piperidine-2,6-dione);

3,3′-((nonane-1,9-diylbis(sulfanediyl))bis(1-oxoisoindoline-4,2-diyl))bis(piperidine-2,6-dione);

3,3′-(((piperazine-1,4-diylbis(octane-8,1-diyl))bis(sulfanediyl))bis(1-oxoisoindoline-4,2-diyl))bis(piperidine-2,6-dione);

3-(5-((5-morpholinopentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((6-morpholinohexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-morpholinoheptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-morpholinooctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((8-(piperazin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(4-methylpiperazin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(4-(4-methylpiperazin-1-yl) piperidin-1-yl)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((8-(piperidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(diethylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(diisopropylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(dimethylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((8-(methylamino)octyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-(3-chloro-4-methylphenyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)ethyl)urea;

1-(3-chloro-4-methylphenyl)-3-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)propyl)urea;

1-(3-chloro-4-methylphenyl)-3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)butyl)urea;

1-(3-chloro-4-methylphenyl)-3-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)pentyl)urea;

1-(3-chloro-4-methylphenyl)-3-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)hexyl)urea;

1-(3-chloro-4-methylphenyl)-3-(7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)heptyl)urea;

3-(4-((8-mercaptooctyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4,4,5,5,5-pentafluoropentyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(cyclohexylamino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((4,4-dimethylcyclohexyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((6-(spiro[5.5]undecan-3-ylamino)hexyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((6-(spiro[3.3]heptan-2-ylamino)hexyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(pyrrolidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(azepan-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(azocan-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(4,4-dimethylpiperidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(3,5-dimethylpiperidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(3-azaspiro[5.5]undecan-3-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((4,4-dimethylcyclohexyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(spiro[3.3]heptan-2-ylamino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-oxo-7-(piperidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N,N-diisopropylheptanamide;

3-(1-oxo-4-((7-(phenylamino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(methyl(phenyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(diphenylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(benzyl(methyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)ethyl)-5-(piperidin-1-yl) pentanamide;

3-(1-oxo-4-((8-oxo-8-(piperidin-1-yl)octyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)-N,N-diisopropyloctanamide;

3-(4-((7-((3,5-dimethyladamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((adamantan-1-yl)oxy)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((adamantan-2-yl)oxy)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(((1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(morpholinomethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((diisopropylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and

1-(3-chloro-4-methylphenyl)-3-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)octyl)urea.

38 . The compound of Formula (Ia) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 1 , wherein the compound is selected from:

2-(2,6-dioxopiperidin-3-yl)-4-((7-(piperidin-1-yl)heptyl)thio)isoindoline-1,3-dione;

4-((5-((adamantan-1-yl)amino)pentyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((6-((adamantan-1-yl)amino)hexyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((7-((adamantan-1-yl)amino)heptyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((6-(((adamantan-1-yl)methyl)amino)hexyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindoline-1,3-dione;

4-((7-(cyclohexylamino)heptyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((7-(spiro[3.3]heptan-2-ylamino)heptyl)thio)isoindoline-1,3-dione;

4-((4-(((adamantan-1-yl)amino)methyl) phenethyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((4-(piperidin-1-ylmethyl) phenethyl)thio)isoindoline-1,3-dione;

4-((4-((cyclohexylamino)methyl) phenethyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((4-(3-(piperidin-1-yl)propyl)benzyl)thio)isoindoline-1,3-dione;

4-((4-(3-(cyclohexylamino)propyl)benzyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((4-(3-morpholinopropyl)benzyl)thio)isoindoline-1,3-dione;

2-(2,6-dioxopiperidin-3-yl)-4-((3-(4-(piperidin-1-ylmethyl)phenyl)propyl)thio)isoindoline-1,3-dione;

4-((3-(4-((cyclohexylamino)methyl)phenyl)propyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((3-(4-(((adamantan-1-yl)amino)methyl)phenyl)propyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

4-((8-((adamantan-1-yl)amino)octyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

3-(4-((5-(3-azaspiro[5.5]undecan-3-yl)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-(3-azaspiro[5.5]undecan-3-yl)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((cyclohexylmethyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclopropylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclopropyl(methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclobutylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(bicyclo[1.1.1]pentan-1-ylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclopentylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((4,4-dimethylcyclohexyl)(methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((cyclohexylmethyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3aR,7aS)-hexahydro-1H-isoindol-2 (3H)-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(tert-butylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((1R,2R)-2-methoxycyclopropyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((1-cyclopropyl-2,2,2-trifluoroethyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-(7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl) azetidine-3-carbonitrile;

3-(4-((7-(3-hydroxyazetidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(3-hydroxy-3-methylazetidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(oxetan-3-ylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3-fluorocyclobutyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3,3-difluorocyclobutyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((2S,3R)-3-hydroxy-2-methylazetidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(3-(trifluoromethoxy) azetidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3,3-difluoro-1-(2-(trifluoromethyl)phenyl)cyclobutyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-((3-(2-(trifluoromethyl)phenyl) oxetan-3-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3,3-difluorocyclopentyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3S,4S)-3-methyl-4-(trifluoromethyl) pyrrolidin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(7-fluoro-5-azaspiro[2.4]heptan-5-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((3-hydroxycyclohexyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

methyl 5-((7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl)amino)-3,3-difluorocyclohexane-1-carboxylate;

3-(4-((7-(3-azabicyclo[3.1.0]hexan-3-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(1,1-difluoro-5-azaspiro[2.4]heptan-5-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(1,1-difluoro-6-azaspiro[2.5]octan-6-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(2-oxa-7-azaspiro[3.5]nonan-7-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-((7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl)amino)bicyclo[1.1.1]pentane-1-carbonitrile;

3-(4-((7-(bicyclo[2.2.2]octan-1-ylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((4-hydroxybicyclo[2.2.2]octan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(8,8-difluoro-2-azabicyclo[3.2.1]octan-2-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(1,4-diazabicyclo[3.2.1]octan-4-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((5-methyloxazol-2-yl)methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

(1R)-1-((7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;

3-(4-((7-((2,4-dimethylpentan-3-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((dicyclopropylmethyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((R)-1-cyclopropylethyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(6-azaspiro[2.5]octan-6-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(isoindolin-2-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(((S)-quinuclidin-3-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(((R)-quinuclidin-3-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-thiomorpholinoheptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(4-(methylsulfonyl)piperazin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(4-(ethylsulfonyl)piperazin-1-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(2-oxopiperidin-1-yl)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(adamantan-1-yl)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-(adamantan-1-ylamino)ethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(adamantan-1-ylamino)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

(3S)-3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

(3R)-3-(4-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(adamantan-1-yl(methyl)amino)ethoxy)butyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(3-hydroxyadamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((adamantan-1-ylmethyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((adamantan-1-ylmethyl)(methyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((6-((1-(adamantan-1-yl)ethyl)amino)hexyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((5-((2-(adamantan-1-yl)ethyl)amino)pentyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(((adamantan-1-yl)methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(adamantan-1-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptanamide;

N-(3,5-dimethyladamantan-1-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptanamide;

N-(adamantan-2-yl)-7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptanamide;

3-(4-((7-((3-chloroadamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((4-chloroadamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-((2-chloroadamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(adamantan-1-yloxy)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(adamantan-2-yloxy)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((adamantan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((1-(adamantan-1-yl)ethyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-ylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(adamantan-1-ylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(4-(adamantan-1-yl(methyl)amino)butyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)acetamide;

3-(1-oxo-4-((5-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)pentyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)hexyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(methyl((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

(S)-3-(1-oxo-4-((4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

(R)-3-(1-oxo-4-((4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(morpholinomethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2,5-dibromo-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2,5-dibromo-4-((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-2,5-dibromobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(azocan-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(4,4-difluoropiperidin-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(6-azaspiro[2.5]octan-6-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(3,5-dimethylpiperidin-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((4-methylpiperazin-1-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((3aR,7aS)-octahydro-2H-isoindol-2-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((((R)-1-cyclopropylethyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(bromomethyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3,5-difluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-fluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2,6-difluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2,3-difluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2,3,5-trifluoro-4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((2,3,5,6-tetrafluoro-4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-chloro-2-fluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-chloro-6-fluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-chloro-5-fluoro-4-(piperidin-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((cyclohexylamino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-fluoro-4-(morpholinomethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((dicyclopropylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((cyclopropylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((bicyclo[1.1.1]pentan-1-ylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-((spiro[3.3]heptan-2-ylamino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((cyclohexylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((cyclohexylmethyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-((((tetrahydro-2H-pyran-2-yl)methyl)amino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(thiomorpholinomethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((diethylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((dicyclohexylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((3-hydroxyadamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((4,4-dimethylcyclohexyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((4,4-dimethylpiperidin-1-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((6-azaspiro[2.5]octan-6-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((3,5-dimethylpiperidin-1-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((3-azaspiro[5.5]undecan-3-yl)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((tert-butylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(azocan-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(2-(piperidin-1-yl)ethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(cyclohexylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-morpholinoethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(diethylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(4-methylpiperazin-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(2-thiomorpholinoethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl) phenethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(piperidin-1-ylmethyl) phenethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((cyclohexylamino)methyl) phenethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(3-(piperidin-1-yl)propyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(3-(cyclohexylamino)propyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(3-((adamantan-1-yl)amino)propyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(3-morpholinopropyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(2-(piperidin-1-yl)ethyl) phenethyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((adamantan-1-yl)amino)ethyl) phenethyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-(4-(piperidin-1-ylmethyl)phenyl)propyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(4-((cyclohexylamino)methyl)phenyl)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(4-(((adamantan-1-yl)amino)methyl)phenyl)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(4-(morpholinomethyl)phenyl)propyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(diisopropylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((2,4-dimethylpentan-3-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(dimethylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(methylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(tert-butylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)methyl) phenethyl)acetamide;

3-(1-oxo-4-((4-(2-(pyrrolidin-1-yl)ethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(azepan-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(4,4-dimethylpiperidin-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(3-azaspiro[5.5]undecan-3-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((3aR,7aS)-octahydro-2H-isoindol-2-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-([1,4′-bipiperidin]-1′-yl)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(cyclopropylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(cyclobutylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(cyclopentylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((dicyclopropylmethyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(((R)-1-cyclopropylethyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(bicyclo[1.1.1]pentan-1-ylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(2-(spiro[3.3]heptan-2-ylamino)ethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((cyclohexylmethyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(dicyclohexylamino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((hexahydro-2,5-methanopentalen-3a (1H)-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((adamantan-2-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((3,5-dimethyladamantan-1-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((3-hydroxyadamantan-1-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(((adamantan-1-yl)methyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-((1-(adamantan-1-yl)ethyl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(2-(((1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl)amino)ethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((4-(2-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)ethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(azocan-1-ylmethyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-((dicyclohexylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(((2,4-dimethylpentan-3-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(((4,4-dimethylcyclohexyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-((spiro[3.3]heptan-2-ylamino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-(((3,5-dimethyladamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-((((adamantan-1-yl)methyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-((3-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((diisopropylamino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((diisopropylamino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(azocan-1-ylmethyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(azocan-1-ylmethyl)-3-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((4,4-dimethylcyclohexyl)amino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-fluoro-4-((spiro[3.3]heptan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-fluoro-4-((spiro[3.3]heptan-2-ylamino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((3,5-dimethyladamantan-1-yl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((3,5-dimethyladamantan-1-yl)amino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((((adamantan-1-yl)methyl)amino)methyl)-2-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-((((adamantan-1-yl)methyl)amino)methyl)-3-fluorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((2-fluoro-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((3-fluoro-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-chlorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-3-chlorobenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-2-methylbenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)-3-methylbenzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)oxy)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((adamantan-1-yl)(methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((3-hydroxyadamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((adamantan-2-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((adamantan-2-yl)(methyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((1-(adamantan-1-yl)ethyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(4-((adamantan-1-yl)(methyl)amino)butyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)acetamide;

3-(5-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((4-(((adamantan-1-yl)(methyl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-(((adamantan-1-yl)amino)methyl)-3-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)thio)ethyl)urea;

3-(5-((7-(cyclopropylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-(cyclobutylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-5-((7-(spiro[3.3]heptan-2-ylamino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-(cyclopentylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-(3-azaspiro[5.5]undecan-3-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((4,4-dimethylcyclohexyl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(5-((7-((3aR,7aS)-octahydro-2H-isoindol-2-yl)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

5-((7-((adamantan-1-yl)amino)heptyl)thio)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;

3-(5-((7-((adamantan-1-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-(((5-(piperidin-1-ylmethyl) furan-2-yl)methyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((5-(morpholinomethyl) furan-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((5-((((S)-1-cyclopropylethyl)amino)methyl) furan-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((5-(azepan-1-ylmethyl) furan-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((5-((cyclopentylamino)methyl) furan-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-(((5-((((tetrahydro-2H-pyran-2-yl)methyl)amino)methyl) furan-2-yl)methyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((5-(((dicyclopropylmethyl)amino)methyl) furan-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((2-(morpholinomethyl)thiazol-4-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-(((2-(piperidin-1-ylmethyl)thiazol-4-yl)methyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((2-(azepan-1-ylmethyl)thiazol-4-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((2-((cyclopentylamino)methyl)thiazol-4-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-(morpholinomethyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-(((4-(piperidin-1-ylmethyl)thiazol-2-yl)methyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-(azepan-1-ylmethyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-((3,5-dimethylpiperidin-1-yl)methyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-((hexahydro-1H-isoindol-2 (3H)-yl)methyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(1-oxo-4-(((4-(thiomorpholinomethyl)thiazol-2-yl)methyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-((diethylamino)methyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-((cyclohexylamino)methyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-(((4-(((cyclohexylmethyl)amino)methyl)thiazol-2-yl)methyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

N-(cyclohexylmethyl)-4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)methyl)thiazole-2-carboxamide;

3-(4-((7-((hexahydro-2,5-methanopentalen-3a (1H)-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((hexahydro-2,5-methanopentalen-3a (1H)-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

(E)-3-(4-((4-(2-bromovinyl)benzyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and

3-(4-((7-(((1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

39 . A compound of Formula (I′)

or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof, wherein

A represents CH 2 or C(O);

B, U, V, and W represent CH;

Y represents O;

R represents S, S(O), or S(O) 2 ;

L represents a linear or branched C 1-40 alkylene group optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof, wherein the linear or branched C 1-40 alkylene group is optionally interrupted one or more times by one or more groups selected from:

O, C(O), S, S(O), S(O) 2 , S(O) 2 N(R 1 ), N(R 2 ) S(O) 2 , C(O)N(R 1 ), N(R 2 )C(O), N(R 3 ), or N(R 4 )C(O)N(R 5 ), wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl,

cycloalkylene optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

arylene optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy,

heterocyclylene optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and oxo,

heteroarylene optionally substituted with substituent(s) selected from the group consisting of halogen, C 1-5 alkyl, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy, or

any combination thereof; and

L 1 represents H or C 1-3 alkyl; and

wherein when L 1 represents H,

X 1 represents NHC(O)R i or SR j , wherein R i and R j each independently represent cycloalkyl optionally substituted with substituent(s) selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof, or

X 1 represents cycloalkyl optionally substituted with substituent(s) selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof; or

when L 1 represents C 1-3 alkyl, X 1 represents:

NR 6 R 7 , wherein R 6 represents H or C 1-6 alkyl, and R 7 represents cycloalkyl optionally substituted with substituent(s) selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, C 1-3 halogenated alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof; or

heterocyclyl, optionally substituted with substituent(s) selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

40 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein

L represents a linear or branched C 1-40 alkylene group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, and any combination thereof, wherein the linear or branched C 1-40 alkylene group is optionally interrupted one or more times by one or more groups selected from:

O; C(O); S; S(O); S(O) 2 ; S(O) 2 N(R 1 ); N(R 2 ) S(O) 2 ; C(O)N(R 1 ); N(R 2 )C(O); N(R 3 ); N(R 4 )C(O)N(R 5 ); wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl;

C 5 -C 14 arylene group optionally substituted with substituent(s) selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or C 1-5 alkyl,

3- to 12-membered heterocyclylene group optionally substituted with substituent(s) selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or C 1-5 alkyl;

5- to 10-membered heteroarylene group optionally substituted with substituent(s) selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or C 1-5 alkyl;

C 3 -C 12 cycloalkylene group optionally substituted with substituent(s) selected from halogen, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, oxo, or C 1-5 alkyl, or

any combination thereof;

wherein R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent H or C 1-3 alkyl.

41 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein L represents the following groups optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof:

linear or branched C 1 -C 40 alkylene; *—(CH 2 ) n1 —N(R 22 ) S(O) 2 —(CH 2 ) n2 —; *—(CH 2 ) n1 —S(O) 2 N(R 23 )—(CH 2 ) n2 —; or *—(CH 2 ) n1 -phenylene-(CH 2 ) n2 —;

wherein * indicates the point of attachment to R;

R 22 and R 23 are each independently selected from H and C 1-3 alkyl;

n1 and n2 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

42 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein L represents the following groups optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof:

—CH 2 —; —(CH 2 ) 2 —; —(CH 2 ) 3 —; —(CH 2 ) 4 —; —(CH 2 ) 5 —; —(CH 2 ) 6 —; —(CH 2 ) 7 —; —(CH 2 ) 8 —; —(CH 2 ) 9 —; —(CH 2 ) 10 —; —(CH 2 ) 11 —; —(CH 2 ) 12 —; —(CH 2 ) 13 —; —(CH 2 ) 14 —; —(CH 2 ) 15 —; —(CH 2 ) 16 —; —(CH 2 ) 17 —; —(CH 2 ) 18 —; —(CH 2 ) 19 —; —(CH 2 ) 20 —; *—(CH 2 ) 2 —NHS(O) 2 —CH 2 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 2 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 3 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 4 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 5 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 6 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 7 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 8 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 9 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 10 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 11 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 12 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 13 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 14 —; *—(CH 2 ) 2 —NHS(O) 2 —(CH 2 ) 15 —; *—(CH 2 ) 3 —NHS(O) 2 —CH 2 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 2 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 3 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 4 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 5 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 6 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 7 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 8 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 9 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 10 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 11 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 12 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 13 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 14 —; *—(CH 2 ) 3 —NHS(O) 2 —(CH 2 ) 15 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 3 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 4 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 5 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 6 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 7 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 8 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 9 —; *—(CH 2 ) 4 NHS(O) 2 (CH 2 ) 10 —; *—(CH 2 ) 5 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 6 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 7 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 8 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 8 NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 9 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 10 NHS(O) 2 (CH 2 ) 1 —; *—(CH 2 ) 5 NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 6 NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 7 NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 8 NHS(O) 2 (CH 2 ) 3 —; * (CH 2 ) NHS(O) 2 (CH 2 ) 2 —; *—(CH 2 ) 10 NHS(O) 2 (CH 2 ) 2 —; *—CH 2 -phenylene-CH 2 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 1 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 5 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 1 —; *—(CH 2 ) 3 -phenylene-CH 2 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 4 -phenylene-CH 2 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 5 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 6 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 7 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 8 -phenylene-CH 2 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 2 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 3 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 4 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 5 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 6 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 7 —; *—(CH 2 ) 8 -phenylene-(CH 2 ) 8 —; *—CH 2 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 2 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 3 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 4 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 5 -phenylene-(CH 2 ) 8 —; *—(CH 2 ) 6 -phenylene-(CH 2 ) 8 —; or *—(CH 2 ) 7 -phenylene-(CH 2 ) 8 —;

wherein * indicates the point of attachment to R.

43 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein L represents the following groups optionally substituted with one or more substituent(s) selected from halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, a 3- to 12-membered heterocyclyl, or any combination thereof:

44 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein

L 1 represents H, and

X 1 represents the following optionally substituted groups:

adamantanyl-C(O)NH—, adamantanyl-S—, or norcamphanyl,

wherein the optional substituent(s) of the optionally substituted group is selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

45 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 44 , wherein X 1 represents:

adamantan-1-yl-C(O)NH—, 3-hydroxyadamantanyl-C(O)NH—, 3-hydroxyadamantan-1-yl-C(O)NH—, 3-chloro-adamantan-1-yl-C(O)NH—, 4-chloroadamantan-1-yl-C(O)NH—, 2-chloroadamantan-1-yl-C(O)NH—, adamantan-2-yl-C(O)NH—, adamantan-1-yl-S—, 3-hydroxyadamantanyl-S—, 3-hydroxyadamantan-1-yl-S—, 3-chloroadamantan-1-yl-S—, 4-chloroadamantan-1-yl-S—, 2-chloroadamantan-1-yl-S—, adamantan-2-yl-S—, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl.

46 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein when L 1 represents C 1-3 alkyl, X 1 represents NR 6 R 7 , wherein R 6 represents H or C 1-3 alkyl, and R 7 represents: adamantanyl, cyclohexyl, spiro-cycloalkyl, or norcamphanyl;

wherein the adamantanyl, cyclohexyl, spiro-cycloalkyl and norcamphanyl are optionally substituted with a substituent(s) selected from C 1-6 alkyl, oxo, halogen, cyano, trifluoromethyl, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, or any combination thereof.

47 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 46 , wherein R 7 represents:

adamantan-1-yl, 3-hydroxyadamantanyl, 3-hydroxyadamantan-1-yl, 3-chloroadamantan-1-yl, 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, adamantan-2-yl, bicyclo[2.2.1]heptan-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, 7,7-dimethylbicyclo[2.2.1]heptan-1-yl, or 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl.

48 . The compound of Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein when L 1 represents C 1-3 alkyl, X 1 represents an optionally substituted piperidinyl, wherein

the optional substituent(s) of said optionally substituted piperidinyl is selected from: C 1-6 alkyl, halogen, oxo, cyano, amino, hydroxy, C 1-3 alkoxy, halogenated C 1-3 alkoxy, halogenated C 1-3 alkyl, di(C 1-6 alkyl)phosphono, C 1-6 alkylsulfonyl, or any combination thereof.

49 . The compound of F Formula (I′) or a salt, a solvate, an isotopically enriched analog, a tautomer, a stereoisomer thereof, or a mixture of stereoisomers thereof of claim 39 , wherein the compound is selected from:

N-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)hexyl) adamantane-1-carboxamide;

3-chloro-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)hexyl) adamantane-1-carboxamide;

3-(4-((7-(adamantan-1-ylthio)heptyl)thio)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;

1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)hexyl)methanesulfonamide;

1-((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)-N-(7-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)heptyl)methanesulfonamide;

3-(4-((7-(adamantan-1-ylamino)heptyl)thio)-1-oxoisoindolin-2-yl)-1-methylpiperidine-2,6-dione;

1-methyl-3-(1-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

1-methyl-3-(1-oxo-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((7-(cyclohexylamino)heptyl)thio)-1-oxoisoindolin-2-yl)-1-methylpiperidine-2,6-dione;

1-methyl-3-(1-oxo-4-((4-(piperidin-1-ylmethyl)benzyl)thio)isoindolin-2-yl)piperidine-2,6-dione;

3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)thio)-1-oxoisoindolin-2-yl)-1-methylpiperidine-2,6-dione; or

1-methyl-3-(1-oxo-4-((7-(spiro[3.3]heptan-2-ylamino)heptyl)thio)isoindolin-2-yl)piperidine-2,6-dione.

50 . A pharmaceutical composition comprising, as an active ingredient, the compound of Formula (I) of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

51 . The pharmaceutical composition of claim 50 , further comprising at least one additional therapeutic agent.

52 . A pharmaceutical composition comprising, as an active ingredient, the compound of Formula (I′) of claim 39 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

53 . The pharmaceutical composition of claim 52 , further comprising at least one additional therapeutic agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2021
From: YANG, XIAOBAO; JIANG, BIAO; QIU, XING; SUN, NING; SUN, RENHONG; LIU, LINYI; REN, CHAOWEI
To: SHANGHAITECH UNIVERSITY
Reel/Frame 058008/0484 →
Priority Claims (1)
CN 201910138460.3 · Feb 25, 2019 · national
Continuity (1)
Related Publication 20220143002A1 · May 12, 2022
References Cited (119)
US 9938264B2 · Crews et al. · 2018 [cited by applicant]
US 9993514B2 · Campos · 2018 [cited by applicant]
US 10385037B2 · Ruchelman et al. · 2019 [cited by applicant]
US 10450310B2 · Gray et al. · 2019 [cited by applicant]
US 10759808B2 · Wang et al. · 2020 [cited by applicant]
US 11104666B2 · Crew et al. · 2021 [cited by applicant]
US 11771709B2 · Yang et al. · 2023 [cited by applicant]
US 12226424B2 · Yang et al. · 2025 [cited by applicant]
US 20060063926A1 · Ma et al. · 2006 [cited by applicant]
US 20060211728A1 · Greig et al. · 2006 [cited by applicant]
US 20080167345A1 · Jones et al. · 2008 [cited by applicant]
US 20100099658A1 · Kondoh et al. · 2010 [cited by applicant]
US 20100204196A1 · Chamberlain et al. · 2010 [cited by applicant]
US 20120028924A1 · Aquila et al. · 2012 [cited by applicant]
US 20120083488A1 · Kinoshita et al. · 2012 [cited by applicant]
US 20120202776A1 · Wang et al. · 2012 [cited by applicant]
US 20130143922A1 · Greig et al. · 2013 [cited by applicant]
US 20130190298A1 · Liang et al. · 2013 [cited by applicant]
US 20150291562A1 · Crew et al. · 2015 [cited by applicant]
US 20160022642A1 · Crews · 2016 [cited by applicant]
US 20180099940A1 · Crew · 2018 [cited by examiner]
US 20220041576A1 · Chen et al. · 2022 [cited by applicant]
US 20220041578A1 · Chen et al. · 2022 [cited by applicant]
US 20220117982A1 · Yang · 2022 [cited by examiner]
US 20220143002A1 · Yang et al. · 2022 [cited by applicant]
US 20220313829A1 · Yang · 2022 [cited by examiner]
US 20230096517A1 · Yang · 2023 [cited by examiner]
US 20230203022A1 · Yang · 2023 [cited by examiner]
CN 1867331 · 2006 [cited by applicant]
CN 101679380 · 2010 [cited by applicant]
CN 102822165 · 2012 [cited by applicant]
CN 103396397 · 2013 [cited by applicant]
CN 103787802 · 2014 [cited by applicant]
CN 106432104 · 2017 [cited by applicant]
CN 106458993A · 2017 [cited by applicant]
CN 108136044 · 2018 [cited by applicant]
CN 108366992 · 2018 [cited by applicant]
CN 109311900 · 2019 [cited by applicant]
CN 109475528 · 2019 [cited by applicant]
CN 105566290 · 2019 [cited by applicant]
CN 109912655 · 2019 [cited by applicant]
CN 109928956 · 2019 [cited by applicant]
CN 110204532 · 2019 [cited by applicant]
CN 110291087 · 2019 [cited by applicant]
CN 110357889 · 2019 [cited by applicant]
CN 110506039 · 2019 [cited by applicant]
CN 11051298 · 2020 [cited by applicant]
CN 110963994 · 2020 [cited by applicant]
CN 111606883 · 2020 [cited by applicant]
JP H02184659 · 1990 [cited by applicant]
JP 2006519827 · 2006 [cited by applicant]
JP 2008513538 · 2008 [cited by applicant]
JP 2010515715 · 2010 [cited by applicant]
JP 2010522170 · 2010 [cited by applicant]
JP 2010535798 · 2010 [cited by applicant]
JP 2011523646 · 2011 [cited by applicant]
JP 2013534221 · 2013 [cited by applicant]
JP 2013539765 · 2013 [cited by applicant]
JP 2017513862 · 2017 [cited by applicant]
JP 2019513746 · 2019 [cited by applicant]
JP 2020504089 · 2020 [cited by applicant]
JP 2022503942 · 2022 [cited by applicant]
JP 2022521746 · 2022 [cited by applicant]
WO 2004080976 · 2004 [cited by applicant]
WO 2008115516 · 2008 [cited by applicant]
WO 2009008371 · 2009 [cited by applicant]
WO 2010143664 · 2010 [cited by applicant]
WO 2016065980 · 2016 [cited by applicant]
WO 2016197032 · 2016 [cited by applicant]
WO 2017079267 · 2017 [cited by applicant]
WO 2017117474 · 2017 [cited by applicant]
WO 2017185036 · 2017 [cited by applicant]
WO 2017176957 · 2017 [cited by applicant]
WO 2017176958 · 2017 [cited by applicant]
WO 2017185031 · 2017 [cited by applicant]
WO 2017197051 · 2017 [cited by applicant]
WO 2017197056 · 2017 [cited by applicant]
WO 2018052945 · 2018 [cited by applicant]
WO 2018052949 · 2018 [cited by applicant]
WO 2018071606 · 2018 [cited by applicant]
WO 2018098288 · 2018 [cited by applicant]
WO 2018102067 · 2018 [cited by applicant]
WO 2018102725 · 2018 [cited by applicant]
WO 2018119441 · 2018 [cited by applicant]
WO 2018119448 · 2018 [cited by applicant]
WO 2018140809 · 2018 [cited by applicant]
WO 2019038717 · 2019 [cited by applicant]
WO 2019079569 · 2019 [cited by applicant]
WO 2019133531 · 2019 [cited by applicant]
WO 2019195609 · 2019 [cited by applicant]
WO 2019196812A1 · 2019 [cited by applicant]
WO 2020006264 · 2020 [cited by applicant]
WO 2020114482 · 2020 [cited by applicant]
WO 2020173426 · 2020 [cited by applicant]
WO 2020198435 · 2020 [cited by applicant]
WO 2021113557 · 2021 [cited by applicant]
WO 2021118629 · 2021 [cited by applicant]
Steinebach “A MedChem toolbox for cereblon-directed PROTACs” Med. Chem. Commun., 2019, 10, 1037-1041 (Year: 2019). [cited by examiner]
International Search Report for PCT/CN2020/076578 mailed Mar. 30, 2020, 9 pages. [cited by applicant]
Written Opinion of the ISA for PCT/CN2020/076578 mailed Mar. 30, 2020, 6 pages. [cited by applicant]
Yiming Li et al., “Selective Late-Stage Oxygenation of Sulfides with Ground-State Oxygen by Uranyl Photocatalysis”, Angewandte Chem. Int. Ed. 2019, first published Jul. 2019, 58, pp. 13499-13506, DOI: 10.1002/anie.20190… [cited by applicant]
Yiming Li et al., “A Highly Efficient Cu-Catalyzed S-Transfer Reaction: From Amine to Sulfide”, Organic Letters, pubs.acs.org/OrgLett, ASC Publications, 2014 American Chemical Society, dx.doi.org/10.1021/015009747, pp. … [cited by applicant]
Donghuai Xiao et al., “Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities”, Science Direct, European Journal of Medicinal Chemistry 176 (avail… [cited by applicant]
Yamazoe et al (Heterobifunctional molecules induce dephosphorylation of kinases-a proof of concept study, ChemRxiv, Jul. 31, 2019, doi.org/10.26434/chemrxiv.9177878.v1). [cited by applicant]
International Search Report for PCT/CN2021/077793, mailed May 26, 2021, 14 pages. [cited by applicant]
Written Opinion of the ISA for PCT/CN2021/077793, mailed May 26, 2021, 19 pages. [cited by applicant]
U.S. Appl. No. 17/922,124, filed Oct. 28, 2022, 89 pages. [cited by applicant]
U.S. Appl. No. 17/632,612, filed Aug. 24, 2022, 287 pages. [cited by applicant]
U.S. Appl. No. 17/801,953, filed Aug. 24, 2022, 103 pages. [cited by applicant]
Lai, Ashton C., Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL, Angewandte Chemie, International Edition, 2016, 55(2), 807-810. [cited by applicant]
Zhang, Chengwei, Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK), European Journal of Medicinal Chemistry, 2018, 151, 304-314. [cited by applicant]
Turk, et. al., Proceedings of the National Academy of Sciences of the United States of America (1996), 93(15), 7552-7556. [cited by applicant]
Ishoey, Mette, Translation Termination Factor GSPT1 is a Phenotypi cally Relevant Off-Target of Heterobifunctional Phthalimide Degraders, A CS Chemical Biology , 2018, 13(3), 553-560. [cited by applicant]
Restriction Requirement issued in U.S. Appl. No. 17/801,953 dated Feb. 5, 2025, 11 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 17/632,612 dated Nov. 27, 2024, 27 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 17/046,690 dated Mar. 25, 2024, 21 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 17/046,690 dated May 24, 2023, 19 pages. [cited by applicant]
Restriction Requirement issued in U.S. Appl. No. 17/046,690 dated May 24, 2022, 11 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 17/046,690 dated Sep. 14, 2022, 31 pages. [cited by applicant]